best practice in crrt anticoagulation - sfai.se · best practice in crrt anticoagulation pierre...
TRANSCRIPT
BestpracticeinCRRTanticoagulation
PierreTISSIERES,MD,PhDPediatricICUandNeonatalMedicineParisSouthUniversityHospitals
Noconflict todiscloseAcknowledge toA.Deep,King’s CollegeHospital,London
• Whydowechangefilters?Iseverythingrelatedtoclottedfilters?
• Whydofilters/circuitsclot?• VariousAnticoagulantsavailable– Actions,advantages,disadvantages
• Isthereasinglebestanticoagulant?• Availableevidence• Inpractice
3
Circuitlifespan:“Host-circuit”determinants
“circuit”factors• flowrate• Filtrationfraction• pre-dilution• cathetersize• anticoagulation
“patient”factors• primarycondition!!• PT/INR• plateletcountandF1• haemoglobin• venousaccessissues• bloodproductsuse.
Reasonforcircuitchange• Clotting• Manufacturerrecommendation(72hours)• accessmalfunction- kinking,bending,leakage,inappropriatelysmallsize
• machinemalfunction• unrelatedpatientindication(e.g.,needsCTscan)• CRRTdiscontinued
5Int J Artif Organs. 2012
Effectsofcircuit/filterclotting
• Decreasedefficacyoftreatment-(importantincircumstanceslikeinALF)
• Increasedbloodlossespeciallyinnewborns• Increasedcosts• Propensitytoincreasedhaemodynamicinstabilityduringre-connection
• Staffdissatisfaction
6
Anticoagulation« cascade »
A“newermodel”ofthecoagulationpathway:importanceofthebalancebetweenpro/anticoag factors
8Acknowledge A.Deep
2- Wheredoesthrombusform?
• Anyblood-artificialsurfaceinterfaceo Hemofiltero Bubble trapo Vascath
• Areasofturbulence/Resistanceo Luer lock connections
/ 3 way stopcocks
Smallvascath sizesandlowerbloodflowsaddtoalreadyexistingchallengesinpaediatric population
PatientrelatedAccessrelatedCircuitrelatedTreatmentrelated
1- FactorsrelatedtoprematureClotting:
IdealAnticoagulation• Readilyavailable• Safe-Selectivelyactiveinthecircuit– minimaleffectsonpatienthemostasis
• Prolongedfilterlifeideally>48hours• Monitoring– RapidandSimple• Rapidlyreversibleincaseofcomplications• Uncomplicated,easytofollowconsistentlydeliveredprotocols-Stafftraining
• CostEffective
• Saline Flushes• Heparin (UFH)• Low molecular weight heparin• Citrate regional anticoagulation• Prostacyclin• Nafamostat mesilate• Danaparoid• Dermatan sulfate• Fondaparinux• Hirudin/Lepirudin• Argatroban (thrombin inhibitor).
Minerva Urol Nefrol. 2016 Feb;68(1):87-104. Epub 2015 Oct 16.Anticoagulation for renal replacement therapy for patients with acute kidney injury.Nongnuch A1, Tangsujaritvijit V, Davenport A.
Heparin • Mostcommonlyusedanticoagulant
• Largeexperience
• Shortbiologicalhalf-life
• Availabilityofanefficientinhibitor
• Possibilitytomonitoritseffectwithroutinelaboratorytests– ACT.
Heparin enhances binding of antithrombin III to factor II & X
Large fragments – Anti IIa ActivitySmall fragments : Anti Xa activity
Acts directly and Metabolised by the liver
Metabolites are eliminated by the kidneys
Plasma half-life is approximately 90 minutes
Heparin– SideEffects
• Bleeding-10-50%(DoseACTadjusted)• HeparinResistance+++(ATreducedinsickpatients+increasedATdegradation)
• HeparinInducedThrombocytopenia(HIT)?Inchildren?(<1to5%)Theantibody–plateletfactor4–heparincomplexsubsequentlybindstoplatelets,inducingplateletactivation,aggregationandactivationofthecoagulationpathways.
• UnpredictableandcomplexpharmacokineticsofUFH
Heparine interfere with inflammation!
LMWH
Advantages DisadvantagesHigher anti Xa activityMore predictable pharmacokinetics-hence more reliable anticoagulant response Reduced risk of bleedingLess risk of HIT
No quick antidoteEffect more prolonged in renal failureSpecial assays to monitor anti-Xa activityIncreased costNo difference in filter life
16
Daltaparin,enoxaprin,and nadroparin
17
Heparin- Summary
• Mostcommonlyused• Easytouse,monitor• Noevidenceondose• Systemicside-effects• Contraindicatedinbleedingpatients
18
Citrateanticoagulation
• Howdoesitwork?• Isthereanadvantageoverheparin?• Whatarethesideeffects?• Howeasyisittouse?• Whataretheprotocols?• Whatisneededtomakeitwork?
Howdoescitratework
• Clottingisacalciumdependentmechanism,removalofcalciumfromthebloodwillinhibitclotting
• Addingcitratetobloodwillbindthefreecalcium(ionized)calciuminthebloodthusinhibitingclotting
• Commonexampleofthisisbankedblood
CONTACT PHASEXII activation
XI IX
TISSUE FACTOR TF:VIIa
THROMBIN
fibrinogen
prothrombin
Xa
Va VIIIa Ca++
platelets
CLOT
monocytes / platelets /
macrophages
FIBRINOLYSIS ACTIVATIONFIBRINOLYSIS INHIBITION
NATURAL ANTICOAGULANTS
(APC, ATIII)
X
Phospholipid surface
Ca+
+Ca+
+Ca+
+Ca+
+Ca+
+Ca+
+
CITRATE
Howiscitrateused?
• Inmostprotocolscitrateisinfusedpostpatientbutprefilter oftenatthe“arterial”accessofthedual(ortriple)lumenaccessthatisusedforhemofiltration(HF)…
• CalciumisreturnedtothepatientindependentoftheduallumenHFaccessorcanbeinfusedviathe3rd lumenofthetriplelumenaccess
(1.5 x BFR) (0.4 x citrate rate)
WhathappenstoCa- citrate?
• Ca-citrategetsfiltered/dialysed• Morethan50%getsremovedindialysate• Remainingenterscirculation– TCAcycle– citricacid(liver,muscle,renalcortex)
• 1mmolcitrate– 3mmolNaHCO3(riskofmetabolicalkalosisandhypernatremia)
• Citrate/Camismatchà hypocalcemia
24
Citrate:TechnicalConsiderations
• MeasurepatientandsystemiCain2hoursthenat6hrincrements
• Pre-filterinfusionofCitrate• AimforsystemiCaof0.3-0.4mmol/l
• Adjustforlevels• Systemiccalciuminfusion
• AimforpatientiCaof1.1-1.3mmol/l• Adjustforlevels
ComplicationsofCitrate:“CitrateLock”
• Seenwithrisingtotalcalciumwithdroppingpatientionizedcalcium
• EssentiallydeliveryofcitrateexceedshepaticmetabolismandCRRTclearance
• Metabolicacidosiswithanenlargedaniongap• Aserumtotaltoioniccalciumratioof≥2.5isassumedtobeacriticalthresholdforthepredictionofcitrateaccumulation
• Rxof“citratelock”• Decreaseorstopcitratefor3-4hrs thenrestartat70%ofpriorrateor Increase D or FRF rate to enhance clearance
CitrateinALFandcardiacfailure?
• Metabolicalkalosis• Metabolizedinliver/othertissues
• Electrolytedisorders• Hypernatremia• Hypocalcemia• Hypomagnesemia
• “Cardiactoxicity”- dysrhythmia• Neonatalhearts
28
CitrateAnticoagulation
• Well-designedandflexibleprotocol• Adjustedtothelocalpreferencesofmodalityanddose• Resultsofionizedcalciummeasurementshouldbeavailable24hoursaday(Keepcircuit[Ca++]levelsaround.30forbestresults)
• Trainingofstaff– understandmonitoringandsideeffectprofile
29
CitrateversusHeparin
P=0.03
Intensive Care Med. 2004 Feb;30(2):260-5. Epub 2003 Nov 5.Citrate vs. heparin for anticoagulation in continuous venovenoushemofiltration: a prospective randomized study.Monchi M1, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P.
Regional citrate anticoagulation was superior to heparin for the filter lifetime
and transfusion requirements in ICU patients treated with CRRT
• Median filter life : Citrate - 70 hr; Heparin - 40 hr
• Spontaneous circuit failure : Heparin -87%;Citrate- 57%
• Median time to spontaneous circuit failure: Heparin 45 hrs; Citrate -140 hrs
• Transfusion requirement :Citrate- 0.2 units/day of CVVH ; Heparin- 1 units/day
FinalDecision– CitratevsHeparin
• Localfamiliaritywithprotocol,patientpopulation
• Heparincommonasvastexperience,easytomonitor,goodcircuitlife
• Problems– Systemicanticoagulation,bleeding
(sometimeslife-threatening),HIT,resistance
• Citrate– comparablefilterlife,noriskofbleeding
Whyiscitratenotthestandardofcare?
v Physician’sperception- useofcitratecomplex,
v Citratemodulenotineverymachine
v Metaboliccomplicationswithregularmonitoring,metabolisminliverdiseasecomplexv Hugetrainingresource
v Cost
• InUK– HeparinisthemostcommonlyusedACGforeaseofuse.
33
CitrateHeparin
• A lipid molecule-eicosanoid • Epoprostenol – synthetic
derivative (Flolan)• Platelet aggregation and
adhesion inhibitor (PGI2)• Heparin sparing effect• Reversibly inhibits platelet
function by diminishing the expression of platelet fibrinogen receptors and P-selectin
• Reduces heterotypic platelet-leukocyte aggregation.
Prostacyclin PGI2
Prostacyclin(PGI2):morethananti-thrombotic!
Kinetics• Halflife– 42seconds
• Vasodilatoreffectat20ng/kg/minute
• Plateleteffectat2-8ng/kg/minute-½life2hours
• Limitedclinicalexperience
• Flolan – epoprostenol sodium
Dynamics• Anti-thrombotic
o Inhibitsplateletaggregationandadherencetovesselwall
• Vesseltoneo ReducesSMCproliferationandincreasedvasodilatation
• Anti-proliferativeo Reducesfibroblasts,increasesapoptosis
• Anti-inflammatoryo Reducespro-inflammatorycytokinesandincreasedanti-inflammatorycytokines
• Anti-mitogenic
Sideeffects
• Limitedclinicalexperience• Scantdataonefficacyandsafety• Hypotension,raisedICP,Hyperthermia• Facialflushing,headache• Ventilation-perfusionmismatching• Costistheuse-limitingfactor
EvidenceforuseofProstacyclin
• NoneoutthereespeciallyinPaediatrics• Dose???• Route-?• Indications-?• Mostworkcarriedoutinpatientswherethereiscontraindicationtoheparin/citrate
Ther Apher Dial. 2015 Feb;19(1):16-22. doi: 10.1111/1744-9987.12224. Epub 2014 Sep 4.Factors affecting circuit life during continuous renal replacement therapy in children with liver failure.Goonasekera CD1, Wang J, Bunchman TE, Deep A.
Plattlets sparing effect !
46patientsonCVVH• Group-1Heparin(6.0+/- 0.3IU/kg/hrforgroup1),• Group-2PGI2(7.7+/- 0.7ng/kg/min)• Group-3PGI2andheparin(6.4+/- 0.3ng/kg/min,5.0+/- 0.4IU/kg/hr)• Filterlife,haemostaticvariablesandhaemodynamicvariablesatvarious
times• Meanhemofilter duration:
ü PGI2+heparin22hoursü Onlyheparin-14.3hoursü OnlyPGI2– 17.8hours
Heparin+PGI2:BetterhemodynamicprofilesEnhancedhemofilter duration
Acknowledge toA.Deep,KCH,London
Summary
• Heparinandcitrateanticoagulationmostcommonlyusedmethods
• Heparin:bleedingrisk• Citrate:alkalosis,citratelock!!!• Evidencefavorstheuseofcitrate(notuniversallyused)
• Prostacyclin:plateletssparingeffect,agoodalternativeinpatientswithliverdisease/bleedingdiathesis,butcostimplications
AnticoagulationinSpecialCircumstances
• Inachild with advanced liver disease ?• Inachild with postarrest /cardiac failure ?• Inachild onECMO?• Inachild inseptic shock ?• Inachild heparin induced thrombocytopenia ?• Inaneonates /premies ?
AnticoagulationinSpecialCircumstances
• Inachild with advanced liver disease:No(orPGI2?)• Inachild with postarrest /cardiac failure:Heparin• Inachild onECMO:Heparin,Citrate(PGI2?)• Inachild inseptic shock:No,heparin• Inachild heparin induced thrombocytopenia:Irudin• Inaneonates /premies:Heparin (PGI2?)
Bestpractice- conclusion
• Noperfectchoiceforanticoagulationexists• Choiceofanticoagulationisbestdecidedlocally• Thinkofpatient’sdiseaseprocess,accessissues,bloodproductuse
Thank you
Andsee you inLisbon forESPNIC2017